Genentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Covered by 3 sources
- Medical Xpress·7h agoNew targeted therapy improved survival for patients with KRAS-mutated lung cancer
Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS-targeted therapy divarasib, according to researchers from The University of Texas…
Read at Medical Xpress → - News-Medical·23h agoNext generation KRAS inhibitor divarasib significantly extends lung cancer survival
Patients with previously treated advanced KRAS G12C-mutant non-small cell lung cancer (NSCLC) lived significantly longer and saw improved disease control when treated with the next-generation KRAS targeted therapy divarasib, according to researchers from The University of Texas…
Read at News-Medical → - Financial Post·1d agoGenentech’s Divarasib Demonstrated Best-in-Class Efficacy, Advancing the Standard of Care in Previously Treated KRAS G12C-mutated Lung Cancer
Divarasib monotherapy demonstrated superior efficacy over first-generation KRAS G12C inhibitors, lowering the risk of disease progression or death by 42% and the overall risk of death by 44%, in the Phase III Krascendo 1 study At the time of primary analysis, divarasib achieved…
Read at Financial Post →
